Banque Cantonale Vaudoise’s Arcturus Therapeutics ARCT Stock Holding History

Banque Cantonale Vaudoise’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400	Closed	-$6K	–	1231
2022 Q2	$6K	Hold	400	–	–	﹤0.01%	1214
2022 Q1	$11K	Hold	400	–	–	﹤0.01%	1199
2021 Q4	$15K	Hold	400	–	–	﹤0.01%	1209
2021 Q3	$19K	Hold	400	–	–	﹤0.01%	1168
2021 Q2	$14K	Hold	400	–	–	﹤0.01%	1184
2021 Q1	$17K	Buy	+400	New	+$23.8K	﹤0.01%	1089

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Banque Cantonale Vaudoise's ARCT Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 400 shares — an estimated $6K sold.

Banque Cantonale Vaudoise first reported a position in ARCT in Q1 2021 and held it in 6 quarters. The position peaked at $19K in Q3 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

Banque Cantonale Vaudoise reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 400 Arcturus Therapeutics shares in Q3 2022, an estimated $6K.
Banque Cantonale Vaudoise first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 6 quarters.
Banque Cantonale Vaudoise's Arcturus Therapeutics position peaked at $19K in Q3 2021.
116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.